Integrating Artificial Intelligence with Biomarkers to Meet the Challenges of Dementia

Dementia, the most common subtype of which is Alzheimer’s disease, represents a significant global and social health challenge. Its effective management is currently hindered by poor access to diagnostic services, a lack of effective treatments and limited post-diagnostic monitoring. This review will explore recent advances in our understanding of key biomarkers underlying the development and progression of Alzheimer’s disease and its associated comorbidities. It will also highlight major data collection efforts in the area and emerging artificial intelligence-based approaches, including imaging, speech, movement, and cognitive data that are being used to improve the risk assessment, diagnosis, and monitoring of Alzheimer’s disease. The development of simple, scalable, and cost-effective artificial intelligence-based tools offers the potential to transform Alzheimer’s disease care through early intervention, more personalised treatment, and improved access to care, offering hope to current and future Alzheimer’s disease sufferers.

Authors

Institutions

Publication Details

Journal
Journal of dementia and Alzheimer's disease
Published
2025-10-22
DOI
https://doi.org/10.3390/jdad2040039
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrating Artificial Intelligence with Biomarkers to Meet the Challenges of Dementia

B. Patel, Claire Ginn, Robert Walker, Garth Cruickshank
Journal of dementia and Alzheimer's disease
Dementia and Cognitive Impairment Research
article

Integrating Artificial Intelligence with Biomarkers to Meet the Challenges of Dementia

B. Patel, Claire Ginn, Robert Walker, Garth Cruickshank
article en

Abstract

Dementia, the most common subtype of which is Alzheimer’s disease, represents a significant global and social health challenge. Its effective management is currently hindered by poor access to diagnostic services, a lack of effective treatments and limited post-diagnostic monitoring. This review will explore recent advances in our understanding of key biomarkers underlying the development and progression of Alzheimer’s disease and its associated comorbidities. It will also highlight major data collection efforts in the area and emerging artificial intelligence-based approaches, including imaging, speech, movement, and cognitive data that are being used to improve the risk assessment, diagnosis, and monitoring of Alzheimer’s disease. The development of simple, scalable, and cost-effective artificial intelligence-based tools offers the potential to transform Alzheimer’s disease care through early intervention, more personalised treatment, and improved access to care, offering hope to current and future Alzheimer’s disease sufferers.

Journal of dementia and Alzheimer's diseaseVol. 2(4)
University of Cambridge (GB), Queen Elizabeth Hospital Birmingham (GB), University of Southampton (GB)
Openalex Percentile: Top 64%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Integrating Artificial Intelligence with Biomarkers to Meet the Challenges of Dementia — B. Patel, Claire Ginn, et al. · Journal of dementia and Alzheimer's disease (2025) | TGRS Research Map | TGRS